Loading patent…
AssigneeGenmab A/S
InventorsJan G. J. van de Winkel, Marcus A. van Dijk, Janine Schuurman, Arnout F. Gerritsen, Ole Baadsgaard, Jørgen Peterson
Estimating the term…
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject an isolated human monoclonal antibody, or antigen binding portion thereof, which binds to human IL-15 and inhibits IL-15 signalling through the IL-15 receptor in an amount effective to treat the disorder and wherein the antibody comprises
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject an isolated human monoclonal antibody, or antigen binding portion thereof, which binds to human IL-15 and inhibits IL-15 sigialling through the IL-15 receptor in an amount effective to treat the disorder and wherein the antibody comprises a human heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2, and a human light chain comprising the amino acid sequence set forth in SEQ ID NO:4.
Dependencies are inferred from the claim text.